SCHEMBL6792827

SCHEMBL6792827

CCCCCCN(C)c1ccc(/C=C2\SC(=S)N(CCNC(C)=O)C2=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MYC P01106 2/20 0.50
▸ MAX P61244 1/20 0.49
▸ MCHR1 Q99705 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ MAPT P10636 3/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ MAOA P21397 2/20 0.47
▸ MAOB P27338 1/20 0.47
▸ DNM1 Q05193 1/20 0.46
▸ PAX8 Q06710 1/20 0.46
▸ NCOA3 Q9Y6Q9 3/20 0.45
▸ MITF O75030 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ FFAR1 O14842 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ CISD1 Q9NZ45 2/20 0.44
▸ NCOA1 Q15788 1/20 0.44
▸ POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6792830 1.00 MYC (0.50) MYCMAXMCHR1ALDH1A1MAPT
SCHEMBL6786621 0.90 MCHR1 (0.45) MYCMAXMCHR1ALDH1A1MAPT
SCHEMBL6786617 0.90 MCHR1 (0.45) MYCMAXMCHR1ALDH1A1MAPT
SCHEMBL7486833 0.86 CISD1 (0.62) MYCMAXALDH1A1MAPTMAOA
SCHEMBL7486836 0.86 CISD1 (0.62) MYCMAXALDH1A1MAPTMAOA
SCHEMBL6786775 0.85 ALDH1A1 (0.47) MYCMAXMCHR1ALDH1A1MAPT
SCHEMBL7489759 0.85 FFAR1 (0.64) MYCMAXMCHR1ALDH1A1MAPT
SCHEMBL7489754 0.85 FFAR1 (0.64) MYCMAXMCHR1ALDH1A1MAPT
SCHEMBL6792514 0.85 MAPK1 (0.60) MYCMAXMCHR1ALDH1A1MAPT
SCHEMBL6792516 0.85 MAPK1 (0.60) MYCMAXMCHR1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-10-07 — — US disclosed
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP disclosed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives APP, PSEN1, PSEN2 MYC 4528/4885MAX 2630/4885MCHR1 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback